Phase 1: testing JMT206 injection for Valid MeSH Conditiongs
Use these resources to provide understandable information about this study to patients, families, and health care providers:
Official registry: https://clinicaltrials.gov/study/NCT07840729 · Shanghai JMT-Bio Inc. · enrollment listed as 90
What this phase means
Phase 1: the first tests in people. The main question is safety and dose, not whether it cures the condition. Groups are small. Side effects are watched closely.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are JMT206 injection, Semaglutide injection, or Placebo injection. The registry lists allocation as randomized. Use these resources to provide understandable information about this study to patients, families, and health care providers:
They plan to enroll about 90 people at Beijing. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Official title (unrewritten)
Identify the Expanded Access Program, if Any. This is Required Unless the Expanded Access Type is "Individual Patients." A Randomized, Parallel, Double-blind, Placebo-controlled Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JMT206 Injection Alone or in Combination With Semaglutide in Obese Participants
Interventions: JMT206 injection, Semaglutide injection, Placebo injection
Primary outcome (registry wording): Incidence of Adverse Events (AE) assessed by CTCAE v6.0
Who it is for (from inclusion criteria)
- Ages 18 Years to 65 Years
- Age 18\~65 (including threshold values), male or female participants;
- Weight change \<5% within the 3 months prior to screening
Who the registry excludes
- People the protocol lists as excluded — the study team must confirm.
Public study contact (from the registry)
Clinical Trials Information Group officer
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
1 listed- Peking University People's Hospital — Beijing, China (recruiting)
FAQ about this NCT record
Is NCT07840729 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07840729?
Phase 1. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07840729?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary